Biogen Inc. raised its full-year sales and earnings guidance Wednesday but said it expects minimal revenue from its Aduhelm drug for Alzheimer's disease through the end of the year.
The Cambridge, Mass.-based pharmaceutical company said it now expects sales of $10.8 billion to $10.9 billion this year, an upward revision from previous guidance of $10.65 billion to $10.85 billion.
Biogen said its adjusted earnings will likely be $18.85 a share to $19.35 a share. The company had previously guided for per-share adjusted earnings of $17.50 to $19.00.
The guidance assumes minimal revenue from Aduhelm this year, Biogen said. The drug gained approval from the Food and Drug Administration earlier this year.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.